Fluent Odra Hybrid Sublingual Drops – 600mg
Hybrid with Indica Qualities
Odra is produced from a hybrid Cannabis sativa and Cannabis indica plant and has a ratio of 60:1 THC:CBD. Patients describe Odra as relaxed, euphoric, and mildly drowsy with an emphasis on its more focused effects on helping to alleviate migraine headaches. Odra is a whole-plant product that contains concentrations of THC, CBD and a full range of other natural components found in cannabis including terpenes, flavonoids and other cannabinoids that contribute to the medicinal properties of cannabis.
Current medical literature supports the use of THC rich products for the treatment of all conditions approved for medical cannabis.
Strain: OG Kush
CBD Content: Approximately 1%
THC Content: Approximately 0.5mg/drop per 600 mg (1 ml)
THC to CBD Ratio: 60:1
Dosing Units: 0.5mg/drop for sublingual drops
Total Doses: 1200 drops per 600 (30ml bottle)
Sold By: Fluent
Leave Your Review: Write A Review[otw_is sidebar=otw-sidebar-6]
Out of stock
Tinctures are absorbed sublingually, so essential cannabinoids are absorbed directly into the bloodstream. Effects are delayed through the absorption process but are prolonged. The application is very discreet, with no odor.
Odra® oil is to be administered orally. The starting dose is 2.5 mg/kg twice daily (5 mg/kg/day). Patients are recommended to initiate treatment on the evening of Day 1 with 2.5 mg/kg. After 5-7 days, the dose can be gradually increased to 5 mg/kg twice a day (10 mg/kg/day).
Patients who are tolerating Odra® at 5 mg/kg twice daily and who may benefit from a dosage increase can be further titrated to a maximum recommended maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). This should be titrated over several weeks, as tolerated. Dosage should not be increased more frequently than every other day.[otw_is sidebar=otw-sidebar-5]
Odra® is contraindicated in patients:
• with hypersensitivity to cannabinoids (e.g., THC or CBD) or to any of the inert ingredients in Odra®;
• with a significant history of cardiovascular disease;
• with an active or previous psychotic or active mood or anxiety disorder; and
• who are pregnant, planning to become pregnant, or are breastfeeding.